Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Role of Brain Imaging in Early Parkinsonism
BMJ 324:d638, Breen,D.P.,et al, 2011
Revascularization of Asymptomatic High-Grade Carotid Stenosis Is Still Indicated in Some Cases
Stroke 42:1152-1153, 1156, Markus,H., 2011
Revascularization of Asymptomatic High-Grade Stenosis Is Not Indicated With Contemporary Stroke Prevention Medical Therapy
Stroke 42:1154-1155, 1156, Ingall,T.J., 2011
A Multidisciplinary Study of Patients with Early-Onset PD with and Without Parkin Mutations
Neurol 72:110-116,106, Lohmann,E.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
High-Resolution Diffusion Tensor Imaging in the Substantia Nigra of De Novo Parkinson Disease
Neurol 72:1378-1384,1374, Vaillancourt,D.E.,et al, 2009
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
[99mTc]TRODAT-1 SPECT Imaging Correlates with Odor Identification in Early Parkinson Disease
Neurol 64:1716-1720, Siderowf,A.,et al, 2005
Excessive Daytime Sleepiness and Subsequent Development of Parkinson Disease
Neurol 65:1442-1446, Abbott,R.D.,et al, 2005
Monoamine Oxide Type B Inhibitors in Early Parkinson's Disease:Meta-Analysis of 17 Randomised Trials Involving 3525 Patients
BMJ 329:593-596, Ives,N.J.,et al, 2004
Autonomic Failure as the Initial Presentation of Parkinson Disease and Dementia with Lewy Bodies
Neurol 63:1093-1095, Kaufmann,H.,et al, 2004
Idiopathic Hyposmia As a Preclinical Sign of Parkinson's Disease
Ann Neurol 56:173-181,169, Ponsen,M.M.,et al, 2004
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Complete Genomic Screen in Parkinson Disease
JAMA 286:2239-2244, Scott,W.K.,et al, 2001
Striatal Dopamine Trnasporter Binding Assessed by [I-123]IPT and Single Photon Emission Computed tomography in Patients with Early Parkinson's Disease, Implications for a Preclinical Diagnosis
Arch Neurol 57:205-208, Schwarz,J.,et al, 2000
The Evolution of Diagnosis in Early Parkinson Disease
ArchNeurol 57:369-372, Jankovic,J.,et al, 2000
The Effect of Estrogen Replacement on Early Parkinson's Disease
Neurol 52:1417-1421, Sanders-Pullman,R.,et al, 1999
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
MRI In Patients with Suspected Vascular Parkinsonism
Neurol 45:2183-2188, Jijlmans,J.C.M.,et al, 1995
Early Differential Diagnosis of Parkinson's Disease with F-flurodeoxyglucose and Positron Emission Tomography
Neurol 45:1995-2004, Eidelberg,D.,et al, 1995
Clinical and[18F]dopa PET Findings in Early Parkinson's Disease
JNNP 59:597-600, Morrish,P.K.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Prognostic Significance of the Onset Mode in Parkinsonism
Neurol 43:829-830, Rajput,A.H.,et al, 1993
PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993
Preclinical Detection of Parkinson's Disease
Neurology Suppl 2, 41:5-921991., Koller,W.C.&Langston,J.W., 1991
Young-Onset Parkinson's Disease:A Clinical Review
Neurol 41:168-173, Golbe,L.I., 1991
False-Negative Results With Levodopa For Early Detection Of Huntington's Disease
NEJM 307:561-562, Myers,R.H.,et al, 1982
Presymptomatic & Early Detection in Huntington's Disease
Ann Neurol 8:343-347, Klawans,H.L.,et al, 1980
Levodopa & Presymptomatic Detection of Huntington's Disease-Eight-Year Follow-Up
NEJM 302:1090, Klawans,H.L.,et al, 1980
Presymptomatic Detection of Huntington's Chorea
BMJ 540, 1972 Sept., , 1972
Use of L-Dopa in the Detection of Presymptomatic Huntington's Chorea
NEJM 286:1332, Klawans,H.,et al, 1972
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017
Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population
Ann Neurol 77:301-311, Rasmussen, K.L.,et al, 2015
"Noncognitive" Symptoms of Early Alzheimer Disease
Neurol 84:617-622, Masters, M.C.,et al, 2015
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Therapeutic Devices for Epilepsy
Ann Neurol 71:157-168, Fisher,R.S., 2012
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012